RenovoRx, Inc. (RNXT) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. I'll be your conference call operator today. Please note that today's call is being recorded and all participants, other than management, are in listen-only mode. There will be a Q&A session following management's presentation. I'll now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead. Thank you, operator. Good afternoon, everyone, and welcome to the Renovo Rep's fourth quarter and full year 2025 financial results conference call. I'm joined today by members of our leadership team, including Dr. Rampant Agha, executive chair and founder, Sean Bagai, chief executive officer, and Mark Vall, chief financial officer. Before we begin, I'd like to remind everyone the statements made during today's call may contain forward-looking statements covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable federal securities laws. These statements, including statements regarding Renovo Rx's clinical and commercial plans, strategies, and estimates, or expectations of financial results, including revenue and operational performance, are based on management's current plans and assumptions, and actual results may differ materially. Please refer to our filings with the SEC, including our Form 10-K, for the year ended December 31st, 2025, for a detailed discussion of the recent uncertainties facing RenovRx. With that, I'll turn the call over to our Chief Executive Officer, Sean Begay. Thank you, Walter, and good afternoon, everyone. Before I walk to our results, I want to acknowledge two important developments in our leadership structure. As we recently announced, Dr. Ramtan Agha, our founder and inventor of our patented TAMP therapy platform, has transitioned to the ...